Terumo Heart Inc. announced that David Seth Feldman, MD/PhD, FACC, FAHA is appointed as the Co-Principal Investigator for its Bridge-to-Transplant trial in the United States to study third generation DuraHeart Left Ventricular Assist System (LVAS). In this role, Dr. Feldman accompanies Dr. Francis Pagani, Director of the Heart Transplant and Center for Circulatory Support at University of Michigan, and Dr. Yoshifumi Naka, Director of cardiac transplantation at NewYork-Presbyterian Hospital/Columbia University Medical Center. Dr. Feldman is Associate Professor of Medicine and Cardiology, with joint faculty positions in physiology and cell biology. He is the Director of Heart Failure and Cardiac Transplantation and Director of Heart Failure and Transplant Fellowship Program at The Ohio State University Medical Center. The DuraHeart System features a small pump implanted in a pocket created in the abdomen. The impeller position is precisely controlled by the electromagnets and sensors to keep it centered within the blood chamber. This happens when the pump is activated. When the magnets in the motor are coupled to the impeller, the motor spins and it causes the impeller to rotate and pump blood from the heart to the body. Once the DuraHeart is running, blood flows from the left ventricle, through the pump and directly to the body via the aorta and provides natural flow produced by the heart by increasing total flow to near normal levels.